Vesting Linked To Improvement of Shareholder Value
QUEBEC CITY, Sept. 17, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX:
CUR)(TCQX: DGCRF) (the "Corporation") reports the granting, as of
today, of 500,000 options to Richard Bordeleau who was appointed Senior
Advisor to the Board on September 1st, 2013. The vesting of these options is tied to the delivery of
measurable milestones of which twenty percent can be vested during Mr.
Bordeleau's mandate as Senior Advisor. The options granted will vest in
several installments which are all linked to strong value-creating
milestones. The other options reported on SEDI are tied to several
stringent vesting conditions, which include the possibility that
Mr. Bordeleau be entrusted with other significant responsibilities. If
any of the milestones do not materialize, then the options related to
this condition will not vest.
"We are granting these options to Mr. Bordeleau because we strongly
believe that his contribution to DiagnoCure will create value for our
shareholders. The vesting will occur as Mr. Bordeleau fulfills his
critical mandates, notably by implementing short-term initiatives and
developing mid- to long-term opportunities" stated Dr. Yves Fradet,
Chairman of the Board and President and Chief Medical Officer.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license on the diagnostic applications of its
proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate
cancer test is commercialized in Europe under CE mark and is approved
for commercialization in Canada and the United States. For more
information, please visit www.diagnocure.com.
This release may contain forwardlooking statements that involve known
and unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the "safe-harbour"
provisions of applicable Canadian securities laws. By their very
nature, forwardlooking statements are based on expectations and
hypotheses and also involve risks and uncertainties, known and unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors and
others in understanding certain key elements of the Corporation's
current objectives, strategic priorities, expectations and plans, and
in obtaining a better understanding of the Corporation's business and
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes and that they
should not place undue reliance on these forwardlooking statements.
For instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based on
management expectations and such outcome may vary materially depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement, and
marketing and distribution challenges. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly update
or revise any forwardlooking statements contained herein unless
required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.